Akathisia …

Stewart A Factor DO

Movement Disorders

Updated 06.19.2024
Released 12.16.1994
Expires For CME 06.19.2027

Akathisia

Author: Stewart A Factor DO

See Contributor Disclosures

Editor: Robert Fekete MD

Akathisia

In This Article

Quick Link

Introduction

Overview

Akathisia is the abnormal state of motor restlessness that is most commonly caused by drugs that block dopamine receptors; it is sometimes perceived as anxiety. It can be an acute or subacute side effect that improves with withdrawal of medication, or it can be chronic or tardive, which occurs after chronic therapy and worsens with drug withdrawal. Literature demonstrates that it occurs with atypical antipsychotics, although perhaps less commonly than is seen with typical agents. The frequency with different agents depends on the D2 blocking effect and dosage. It can also be caused by antidepressants and other drugs. The treatment is different for acute and tardive forms. For the acute form, lowering the dose, withdrawal of the causative agent, or substituting a lower potency drug is the first step. This may be followed by the use of propranolol, mirtazapine, and trazodone, if necessary. These agents can be helpful for the tardive form, but other drugs for tardive dyskinesia may also be tried, including vesicular monoamine transporter type 2 (VMAT2) inhibitors.

Key points

	• Akathisia is a sensorimotor syndrome.
	• Motor symptoms appear to be in response to a variety of sensory symptoms and are stereotyped and suppressible. They decrease with distraction and are often referred to as “unvoluntary.”
	• Sensory symptoms are urges or other uncomfortable phenomena that partially improve with movement.
	• Akathisia occurs acutely or subacutely with dopamine receptor-blocker therapies and improves with removal of the drug. It can also develop as a chronic or tardive disorder, occurring after chronic therapy, and may worsen with removal of the drug.
	• Mechanisms relate to impact of dopamine, serotonin, and noradrenergic systems on the somatosensory system in the brain.
	• There should be a high index of suspicion as akathisia is frequently underrecognized.
	• Akathisia is a complication of all typical, atypical, and third-generation antipsychotics.
	• First-line therapies include propranolol, mirtazapine, vitamin B6, or trazodone.

Historical note and terminology

The term “akathisia” is from the Greek “inability to sit,” but it generally refers to an aversion to being still that is relieved by movement. The term was first used medically by Haskovec (40) who thought the symptoms were the result of psychological disorders (01). A Czech neuropsychiatrist and a former student of Charcot, Haskovec obviously described this phenomenon in the pre-antipsychotic era (76). Akathisia was recognized as a complication of parkinsonism during the epidemic of encephalitis lethargica in the 1920s, and later, Parkinson disease. Dopamine receptor-blocking drugs for the treatment of psychosis were developed during the 1940s, and akathisia was recognized as a side effect of promethazine in 1947 (01). Tardive akathisia, occurring after chronic neuroleptic therapy and remaining and worsening after withdrawal of the drug, was first reported in 1960 (56) but was not labeled “chronic akathisia” until 1983 (09). Akathisia is one of the most troublesome aspects of tardive dyskinesia (120; 101).

Clinical manifestations

Presentation and course

Akathisia is the abnormal state of excessive restlessness. It fundamentally has two components: (1) a sensory component, which includes a sensation of inner restlessness, an urge to move, and dysphoria and (2) a motor component, manifested as movements that result from and relieve the sensation (67). Thus, akathisia is one of several movement disorders manifested by both motor and sensory phenomena (87; 80). Patients describe feeling an overwhelming inability to remain still. The sensation is often unbearable and unpleasant, and patients may feel an associated tension, anxiety, irritability, aggressiveness, and impatience (65; 28; 08; 50). The patients describe feeling jittery, fidgety, and nervous. Akathisia is often accompanied by depression, including possible suicide attempts (08; 50). This is true even with newer antipsychotics. Some studies suggest that suicide attempts are more closely associated with subjective sensory symptoms than motor symptoms, and attentional impairment (104; 105). However, one systematic study indicated no clear association between akathisia and suicide risk (97). This requires further study. Worst of all, movement provides only brief relief. The sensory components can also be relieved by passive movement or a perception of movement, such as riding in a car (87). The movements secondary to restlessness are often stereotyped and specifically involve the lower limbs, including pacing, walking in place, body rocking, leg swinging, toe-tapping, and an inability to stay in one place (tasikinesia) (10; 13; 01). As the movements are the result of sensory phenomena and are distractible, they are often referred to as “unvoluntary” (80). Akathisia can interfere with activities of daily living and can be disabling. The restless movements in the legs associated with akathisia must be differentiated from those involved in the leg stereotypy syndrome, which is a much more common movement disorder (48; 68). In contrast to akathisia, leg stereotypy syndrome is not associated with uncomfortable restlessness; it typically consists of stereotypical, repetitive, flexion-extension, abduction-adduction movement of the legs or tapping of the feet. The movements are suppressible and decrease with distraction. Restless leg syndrome is another syndrome difficult to differentiate because it has a sensory component but is diurnal in nature (80).

Akathisia has been found during any stage of Parkinson disease (62) but may be associated with greater severity of motor symptoms (21). About 50% of patients experience akathisia as a fluctuating phenomenon that may be present when on or off (124; 05). Parkinson disease has been associated with restless leg syndrome, with prevalence as high as 20%, but some of those patients may have akathisia (84).

In relation to dopamine receptor-blocking agents, akathisia may occur as an early acute or subacute side effect (82) or as a tardive phenomenon after chronic administration and a worsening with withdrawal of the agent (09). In the early acute form, patients occasionally develop akathisia abruptly at the onset of oral treatment, sometimes within an hour of receiving the drug (10). In an examination of akathisia frequency post single dose for acute headache management, akathisia was reported at rates of 1.5% for metoclopramide, 1.3% for prochlorperazine, and 1.2% for olanzapine (18). However, in most patients with neuroleptic-induced akathisia, onset is more gradual and occurs after several weeks of continued therapy; 90% of cases occur within 90 days of onset or change of therapy (16). It appears to be drug and dose dependent (125). In a meta-analysis of 98 studies (34,225 participants) of randomized controlled trials that investigated monotherapy of 17 antipsychotics (excluding clozapine), it was found that akathisia development depended on which antipsychotic was used and that it was dose related (125). For example, sertindole and quetiapine carried negligible risks for akathisia across examined doses, whereas most of the other antipsychotics had their risks increase initially with increasing doses, with the maximum risk being seen with risperidone at 5.4 mg/day and lurasidone at 240 mg/day. Akathisia may aggravate the psychopathology for which the neuroleptic is given, partially because of noncompliance with the medication (25). Tardive akathisia occurs after prolonged exposure to neuroleptic drugs (typical and atypical) (78; 43). It can occasionally evolve from acute to tardive akathisia, so-called acute persistent akathisia (also referred to as “chronic akathisia” in the literature) (109). In contrast to the early subacute variety, tardive akathisia typically appears or worsens with dosage reduction or drug withdrawal (61) and is suppressed by dosage increases. Diagnostic criteria include the occurrence during or within 3 months of cessation of neuroleptic therapy and must be persistent when the neuroleptic is stopped for at least 1 month (109). In most cases, tardive akathisia is associated with other tardive syndromes, particularly classical tardive dyskinesia. The persistent nature of tardive akathisia is similar to tardive dyskinesia in that it rarely remits (20; 130).

Some patients have the movements of akathisia without the sensory component, which is referred to as pseudoakathisia or stereotypy (01; 80). This may occur in psychotic patients who cannot verbalize the sensory phenomena but also is associated with the movements of tardive dyskinesia or tardive stereotypy and leg stereotypy syndrome. These patients may be misdiagnosed with other psychiatric states such as mania or agitated depression.

Prognosis and complications

Akathisia found in association with Parkinson disease responds inconsistently to antiparkinsonian therapy (62). Subacute drug-induced akathisia will persist as long as the agent is taken; however, the severity may fluctuate. It will resolve on discontinuation of the drug. Tardive akathisia remits only rarely (13), usually persisting indefinitely without treatment. Particular importance should be connected with the risk of medication noncompliance and suicide.

Clinical vignette

A 68-year-old woman with Huntington disease for over 10 years had chorea, gait disorder with occasional falls, and cognitive dysfunction. She also had a history of obsessive-compulsive symptoms and anxiety treated with sertraline. For increasing chorea, she was placed on tetrabenazine with an escalating dose to 12.5 mg three times daily. After about 6 months, she developed what appeared to be increased movements and depression. The tetrabenazine was initially decreased but then in the emergency room was increased again because of concern that the movements represented increasing chorea. On admission, it was found that the movements were, in fact, severe restlessness. She was getting up constantly. She described dysphoria and a need to move. Because of this, her frequency of falling was increased substantially. The symptoms were so severe she was not sleeping, and she had suicide ideation. The tetrabenazine was tapered off, and low-dose quetiapine was initiated along with an increase in her sertraline. Her chorea increased, but the akathisia, depression, and suicidality all improved, and she was discharged.

Biological basis

Etiology and pathogenesis

Because akathisia is a sensorimotor disorder, the causative abnormality involves complex somatosensory systems. The basal ganglia are central to most movement disorders, and although they do not directly receive sensory information, they process sensory information indirectly and serve as the gatekeeper for sensory input to motor and other nonmotor features (through their anatomically distinct loops) at various levels. Abnormal sensorimotor integration may be key in the pathogenesis of akathisia and other movement disorders that involve sensory features (87). The situations in which akathisia occurs indicate that loss of dopaminergic function is central to its development. Akathisia arises in three main clinical situations, all of which impact dopaminergic systems: (1) Parkinson disease, (2) dopamine receptor-blocking drug (neuroleptic) treatment (dopamine D2 receptor blockade), and (3) treatment with other medications that impact dopamine systems, including VMAT2 inhibitors (eg, tetrabenazine, valbenazine, deutetrabenazine, and reserpine) (83; 49; 103). Although it is suggested that atypical antipsychotics have a lower propensity to cause akathisia than typical agents, it is known that both have the potential to cause it depending on dose and potency (64). Antiemetic dopamine receptor blockers (ie, metoclopramide and promethazine) can also cause akathisia (02). Subacute akathisia is a dose-related phenomenon. Individual susceptibility to anti-dopaminergic drug-induced akathisia may be determined by dopaminergic genetic factors (eg, in the dopamine D3 receptor gene or the A1+ variants of the DRD2/ANKK1 Taq1A allele) (26; 64). Beyond dopamine receptor blockade, it has also been speculated that pre- and postsynaptic mechanisms may lead to a combination of hypo- and hyperdopaminergic states, the latter possibly leading to the hyperactivity (87), as seen in restless legs syndrome. D1 and D2 connections and dopamine autoreceptors may be in play (31). Furthermore, acute drug-induced akathisia, restless legs syndrome, and opioid-withdrawal restlessness, which are phenotypically similar, have other similarities, including responsiveness to opioids, such as codeine, although the data on akathisia are less strong than the others. This is particularly true for the acute versus the tardive type, suggesting a mediating role for the μ-opioid receptor, which is located in the basal ganglia and interacts with dopaminergic pathways, particularly D1 pathways. Further work needed is needed in this area.

Pharmacologic studies have implicated several other nondopaminergic pathways in the pathophysiology of akathisia. The development of akathisia with atomoxetine therapy and the response of many patients to beta-blockers suggests that noradrenergic hyperactivity may play a role (127). Serotonin mechanisms, and specifically 5-HT2 receptor stimulation, have been implicated by pharmacologic studies, demonstrating that SSRI agents such as fluoxetine can cause akathisia (66; 34), and relief may be seen with 5-HT2A/2C receptor antagonists (90; 63). Up to 25% of those treated with fluoxetine may develop akathisia (66; 37). Serotonin acts by inhibiting dopamine release.

It has been hypothesized that dopaminergic blockade occurring within the nucleus accumbens is important to the development of akathisia in relation to other nondopaminergic pathways (110). It has been suggested that the decreased dopaminergic stimulation of the core of the nucleus accumbens and increase in the adrenergic input from the locus ceruleus to the shell portion of the accumbens results in symptoms of akathisia. The increased noradrenergic outcome is the result of a D2 receptor blockade in the locus ceruleus. This mismatch between activities of the core and shell leads to the seemingly senseless and purposeless movements, as seen in obsessive-compulsive disorder. The movements are associated with activation of the shell region (which receives projections from the infralimbic cortex) and immediate reward-seeking behavior due to decreased activity of the core region, both related to akathisia. This may explain the response to beta-blocking agents.

Dopaminergic blockade also leads to downregulation of GABAergic activity, as well as increased release of acetylcholine, particularly from striatal interneurons. These changes could also play a role in the development of akathisia and have led to the study of medications that alter both systems (79).

An association between akathisia and abnormalities of iron metabolism has been proposed based on the similar association of iron and restless legs syndrome. Several studies have found low iron and ferritin levels and high total iron-binding capacity in schizophrenic patients with akathisia (57; 102). In a study, schizophrenic patients without akathisia posted results on all three tests that were intermediate between those of akathitic patients and controls (57). However, this is not a consistent finding, and the role of iron in this disorder remains to be clarified (99).

Epidemiology

The prevalence of acute or subacute akathisia from first-generation neuroleptics over many studies and many years was found to be variable, from as low as 3% to as high as 75%, with an estimate 20% to 30% overall (01). The variation depended on the definition of akathisia as well as risk factors, including type, dose, potency of the neuroleptic, psychiatric diagnosis, female gender, age, ethnicity of the patient population, concomitant features, and recognition of the disorder. For second-generation agents, of the 372 patients with schizophrenia and schizoaffective disorder evaluated in a prevalence study through the FACE-SZ data set from 10 schizophrenia centers in France, the global prevalence was 18.5% (06). In a 9-month, cross-sectional study in Tunisia of 124 outpatients with schizophrenia, schizoaffective disorder and bipolar disorder treated with first- and second-generation drugs, on one month of stable therapy, 19.5% were found to have akathisia (50). In other studies, the frequency was thought to be equal or higher in patients with bipolar disorder than with schizophrenia, about 24% higher overall, although it depended on the drug (12; 52; 88; 22; 19). Controlled trials have demonstrated frequencies of akathisia in 13% to 24% (depending on dose) of bipolar I disorder patients treated with lurasidone (53), in 5% to 8% of patients acutely treated with brexpiprazole for bipolar mania (119), and in 17% of patients with bipolar I or II treated with cariprazine (126).

A meta-analysis of 58 studies demonstrated that the estimated weighted odds ratio of akathisia under second-generation antipsychotics, compared with placebo, was 2.43 (95% CI 1.91-3.10) (23). Nevertheless, in a review of over 70 trials involving atypical antipsychotics, the frequency was consistently lower than that seen with first-generation drugs (52; 58). The same conclusion was reached when accounting for only low doses of first-generation agents (69). One additional study demonstrated lower frequency of akathisia in first-episode psychosis (39). The frequency has been suggested to be about 15% overall with second-generation agents (22). On the other hand, the frequency of acute akathisia was actually high in a study of 129 severely ill patients with first-episode schizophrenia spectrum disorders who were previously naïve to antipsychotics: 42% with risperidone and aripiprazole (129). In a study from Estonia, the frequency of akathisia remained at 30% in an inpatient cohort that was initially on first-generation agents and then changed to second-generation agents 8 years later (86). The results of such comparison studies with first-generation agents depended on the comparator agent; for example, studies with haloperidol were different from those with perphenazine (16).

Several studies have demonstrated that the frequency of akathisia depends on the potency of the second-generation agents. A meta-analysis showed that olanzapine and quetiapine had a low frequency of 4%, whereas it was 20% with other second-generation agents and 50% with haloperidol (100; 28). In a study examining the incidence of acute akathisia, a pooled analysis was completed for three prospective, randomized, flexible-dose, and open-label clinical trials including 493 patients with first-episode nonaffective psychosis in Spain (51). Akathisia was determined using the Barnes Akathisia Rating Scale at 6 weeks after antipsychotic initialization. The overall incidence of akathisia was 19.5%, with significant differences between drugs: haloperidol (57%), risperidone (20%), aripiprazole (18.2%), ziprasidone (17.2%), olanzapine (3.6%), and quetiapine (3.5%). Another meta-analysis of 56 studies examined the frequency with specific second-generation agents. The estimated weighted mean incidence rate of akathisia was 3.9% (95% CI 2.4-6.3) for iloperidone, 6.8% (95% CI 5.1-9.0) for asenapine, 10.0% (95% CI 7.4-13.5) for brexpiprazole, 12.7% (95% CI 10.1-16.1) for lurasidone, and 17.2% (95% CI 13.4-22.1) for cariprazine (23). In this study, type of medication (p < 0.0001), diagnosis (p = 0.02), and race (p = 0.0003) significantly explained part of the heterogeneity of the incidence estimates of akathisia between studies. Similar results have been reported by Chow and colleagues, who examined 177 double-blind and open-label trials of the nine newest atypical agents (19). In a long-term study of asenapine, the figures ranged from 1% to 8% depending on duration and dose (55). Although lower figures have been reported with quetiapine and clozapine, they can still be implicated (74; 106). In a community-dwelling population, the frequency of akathisia was lower with quetiapine and amisulpride, with prevalence figures of 1% to 6% (06). A study in patients with bipolar disorder demonstrated a frequency of 5% with 300 and 600 mg per day of quetiapine (22). It should be noted that frequencies with haloperidol in these comparator studies was quite varied, as earlier studies noted. As mentioned previously, the dose of the drug also appears to be important. This was shown in a meta-analysis of 98 randomized controlled trials (34,225 participants) that investigated monotherapy of 17 antipsychotics (including haloperidol and excluding clozapine) in adults with acute schizophrenia (125). Although the dose appears to be important in relation to the frequency of akathisia, it does not appear to be a factor in the severity (19; 128). In other studies, age appeared to play a role. With aripiprazole, the prevalence was 17% in older and 26% in younger depressed patients (111).

The Genetic Risk and Outcome of Psychosis study is a longitudinal study of 1120 patients with nonaffective psychosis in a younger group with a mean age of 27. Prevalence, incidence, and persistence rates for akathisia were 9%, 5%, and 17%, respectively (71). A study in adolescents demonstrated an approximately 11% frequency with atypical antipsychotics (36). Risk factors for acute akathisia include age, ethnicity, higher antipsychotic doses, high-potency agents, or polytherapy with combinations of atypical agents with other psychotropic drugs (as high as 35% prevalence or 2- to 3-fold increased risk), and bipolar disorder (35; 58; 06).

In nonpsychiatric populations, the risk seems lower; 297 patients undergoing general anesthesia for ambulatory surgery were randomized to receive postoperative nausea/vomiting prophylaxis with droperidol (0.625 mg or 1.25 mg) or ondansetron 4 mg. One out of 18 (6%) in the ondansetron 4 mg group, 1 of 84 (1.2%) in the droperidol 0.625 mg group, and 3 of 87 in the droperidol 1.25 mg (3.4%) group developed akathisia (17). In another study, from a chart review of 592 oncology patients treated with dopamine-blocking antiemetics and referred to a psychiatry service, 4.7% were diagnosed with antiemetic-induced akathisia, which generally took 4 to 6 months to diagnose (95). Studies examining the frequency of akathisia in migraine patients who received single doses of prochlorperazine or metoclopramide had a frequency of 5% to 6% with a definitive diagnosis of akathisia, but 34% had symptoms suggesting a possible diagnosis of akathisia (117; 32). However, in a retrospective observational cohort study of patients presenting to a large urban level one trauma center, rates of akathisia were lower: 1.5% for metoclopramide, 1.3% for prochlorperazine, and 1.2% for olanzapine (18). The rate of delivery of antiemetics (metoclopramide) may impact the frequency of akathisia (123). In a blinded trial, the incidence of akathisia was observed to be 26% with bolus therapy and 7% in those given a slow infusion (118).

The prevalence of tardive akathisia is estimated at approximately 20% to 30% of cases treated chronically with neuroleptics (09), a figure similar to that of classical tardive dyskinesia (29). In general, figures on tardive syndromes have been examined through meta-analyses of large numbers of patients to determine the frequency caused by first- and second-generation antipsychotics. In 41 trials (n=11,493), the prevalence rate of tardive syndrome was 21% for second-generation agents and 30% for first-generation agents (14). Annual incidence was 2.6% for second-generation agents and 6.5% for first-generation drugs (15). There have been reports of tardive akathisia caused by lurasidone (116) and others. Two centers that previously reported large numbers of patients suggested wide variations in the frequency of diagnosis (13). Studies have implied that tardive akathisia occurs more commonly in younger patients treated with higher doses, but it is unclear if there is a gender predilection.

Patients with Parkinson disease show a comparable rate of development of akathisia--26% in one series (62) and 45% in another (21). For up to half of the patients, akathisia relates to nonmotor fluctuations (124; 05).

There have been several studies implicating selective serotonin reuptake inhibitors, such as fluoxetine and sertraline. The frequency of akathisia with these agents is unknown, but it appears to be less than that seen with antipsychotics (01). One study, however, suggested a frequency as high as 25% (66). In a double-blind, placebo-controlled study of patients with Huntington disease treated with tetrabenazine, the frequency of akathisia was 9% of 54 patients (46). The figures for the newer VMAT2 inhibitors, deutetrabenazine and valbenazine, which have been approved for the treatment of tardive dyskinesia and Huntington disease, appear to be lower (81; 45; 47; 42; 30; 103). Other drugs with the potential to cause akathisia include calcium channel blockers, lithium, atomoxetine, and pregabalin (80). The SARS-CoV-2 therapy nirmatrelvir/ritonavir has been reported to cause akathisia as well (85).

Management

Acute akathisia algorithm

(Contributed by Dr. Stewart Factor.)
Tardive akathisia algorithm

(Contributed by Dr. Stewart Factor.)

It is important that psychiatric patients be informed about the possible development of akathisia or other movement disorders if neuroleptic therapy is being prescribed. Recognition is important for patients and physicians, lest they misinterpret the condition as worsening agitation or psychosis; recognition is also important for maintenance of medication compliance and prevention of secondary suicide ideation (24). Should acute or subacute akathisia occur, the first step in therapy is to reduce or eliminate intake of the offending drug (92). Time to reversal after removal of the inciting agent is variable, and there may be a worsening before it improves (16). If withdrawal is not feasible, consider substituting the agent with a less potent one, preferably a second-generation agent (92). If the substitution is unsuccessful, medical therapy will be necessary. There are no treatments specifically FDA-approved for akathisia. However, akathisia may respond to a variety of medications for which there is ample evidence (92; 28).

Anticholinergic medications (including diphenhydramine) have historically been utilized to treat akathisia--perhaps because of their usefulness in drug-induced parkinsonism and acute dystonia, but evidence is scant. A Cochrane review in 2006 found no relevant randomized controlled trials and, hence, no reliable evidence to support or refute the use of anticholinergics for patients with acute or subacute akathisia (96). Several class III and IV trials have been reported (92). Several trials have demonstrated mixed results with various agents in the class. In 2007, a double-blind, placebo-controlled study of biperiden injections was completed in 30 patients (15 active versus controls) with assessments at baseline and three times after the first injection at 2-hour intervals. Response was defined as at least a 2-point decline in the global akathisia score. The numbers of responders in the two groups were not significantly different, and the changes in the Barnes Akathisia Rating Scale were similar (04). A review of five studies and 1094 patients demonstrated that prophylactic use of diphenhydramine had no impact on the development of akathisia (77). A systematic review of the use of anticholinergics prophylactically in the emergency department when neuroleptics or metoclopramide are used to treat headache found the same result (72). Anticholinergics do not appear to be an effective treatment for akathisia and have troublesome adverse effects associated with use. They should not be used. Overall, the level of evidence is 1, and the recommendation grade is B (92).

The current first choice for treating akathisia is the beta-blocker propranolol, which has been in use since 1983. Seven class II and III open-label and controlled trials have shown consistent results with doses of 120 mg/day or less and a 50% improvement (73; 01; 92). Propranolol has been reported to improve tardive dyskinesia as well and may be useful for tardive form of akathisia (41). Other nonselective beta-blockers such as nadolol and pindolol have been found to be effective, though less so because of diminished blood-brain barrier penetration. B1 selective agents, such as metoprolol and betahexol, have also been utilized with some success. These medications should be used with caution in those with depression, pulmonary disease, diabetes mellitus, or cardiac disease. Its side effects include orthostatic hypotension, bradycardia, and exercise intolerability. Overall, the level of evidence is 1, and the recommendation grade is B (92).

5-HT2a antagonists, including mianserin, mirtazapine, and trazodone, represent another approach to treating antipsychotic-induced akathisia, with accumulating evidence supporting their use (91). The basis of their use relates, in part, to the lower propensity of antipsychotics with strong inhibition of 5-HT2a receptors to cause akathisia. Data support their use in akathisia secondary to first- and second-generation antipsychotics. In a systemic review and evidence-based meta-analysis, six randomized controlled trials were found examining 5-HT2a antagonists, five of which included a placebo control group (63; 92). The overall effect size in the analysis is substantial, RR=7.10 with 95% CI 3.08–16.40 (p< 0.0001) based on change in the Barnes Akathisia Rating Scale. Because of the small number of trials, a difference between the three agents: mianserin, mirtazapine, and trazodone, could not be detected. These findings point to the class of 5-HT2a antagonists as effective and safe for neuroleptic-induced akathisia. Overall, the level of evidence for 5HT antagonists is 1, and the recommendation grade is B (92). Some of these trials are discussed.

Mianserin is a tetracyclic antidepressant that demonstrates notable 5-HT2a and 5-HT2c antagonism and also has antihistaminergic and alpha-2 antagonistic activity but limited anticholinergic effects. It is not approved for use in the U.S. One study compared the efficacy of vitamin B6, mianserin, and placebo in the treatment of acute akathisia. Sixty schizophrenia and schizoaffective in-patients with akathisia were randomized to receive vitamin B6 1200 mg/d, mianserin 15 mg/d (low dose), or placebo for 5 days, in a double-blind design. Compared with the placebo group, the vitamin B6-treated and mianserin-treated patients showed a significant improvement in the subjective symptoms (P < 0.0001), subjective distress (P < 0.0001), and global (P < 0.0001) subscales. A reduction of at least 2 points on the Barnes Akathisia Rating Scale global subscale was noted in the vitamin B6 group (13/23, 56%) as well as in the mianserin groups (13/20, 65%) and in only one patient in the placebo group (1/17, 6%; P < 0.0005) (75). There was one other study of B6 that was positive. It is recommended only for short-term use in those who fail other therapies. Overall, the level of evidence for vitamin B6 is 1+, and the recommended grade is A (92). B6 toxicity, particularly peripheral neuropathy, must be monitored.

Mirtazapine is a potent antagonist of central alpha-2 auto- and hetero-adrenergic receptors, as well as an antagonist of 5-HT2A/2C, 5-HT3, and histaminergic H1 postsynaptic receptors. The use of mirtazapine offers advantages over other anti-akathisia drugs in its better adverse effect profile as well as its ability to treat coexisting depression (94). In a 7-day double-blind trial, 90 patients treated with antipsychotics meeting DSM-IV criteria for akathisia were randomly assigned to mirtazapine (n = 30; 15 mg), propranolol (n = 30; 80 mg), or placebo (n = 30). Twenty-four patients (26.6%) did not complete the study (seven mirtazapine, eight propranolol, nine placebo) due to lack of response (n = 19) and adverse events (n = 5). Both mirtazapine and propranolol significantly reduced akathisia severity (Barnes Akathisia Rating Scale: -34% mirtazapine (p = .012) and -29% propranolol (p = .023) vs. placebo -11%). Thirteen (43.3%) mirtazapine- and nine (30.0%) propranolol-treated patients versus two (6.7%) placebo-treated patients responded (BARS global scale reduction ≥ 2; odds ratios 10.7 [95% confidence interval (CI), 2.1-53.3] and 6.0 [95% CI, 1.1-30.7]). Five (16.7%) of 30 propranolol-treated patients and none in the mirtazapine and placebo groups (p = .0195 for both) prematurely discontinued the study due to clinically significant hypotension or bradycardia (90). In a meta-analysis that included this trial and a smaller trial, the risk ratio for response was 6.67 (95% CI 2.14–20.78; p = 0.001) and for remission was 6.20 (95%CI 1.74–22.08; p = 0.005), respectively, indicating that mirtazapine is about six times more effective than placebo in ameliorating symptoms of acute akathisia (91). The most common adverse effect was mild sedation. Increased appetite and subsequent weight gain may also be an issue. There have been rare reports of mirtazapine causing akathisia. The mechanism by which this occurs is unknown, but treating physicians should be aware of this possibility (98).

Trazodone has potent serotonin 5-HT2a receptor agonist and alpha-1 adrenergic receptor antagonist effects and is a weak serotonin reuptake inhibitor and a weak histamine H1 receptor antagonist. A double-blind, crossover study of trazodone has also been found to improve akathisia. This was a 6-day study (3 days active, 3 days placebo with no washout) performed on 13 patients with acute akathisia diagnosed by DSM IV criteria. There was significant improvement of the Barnes Akathisia Rating scale subjective, objective, distress, and global parts with 100 mg at night (112). This study was followed by a double-blind, placebo-controlled, 5-day trial of trazodone 50 mg per day in 52 patients with mild to severe akathisia (107). The study showed a significant improvement in objective (P = 0.01) and subjective (P = 0.001) symptoms of akathisia, as well as significant change in global clinical assessment (P = 0.001). It was also well tolerated.

Gabapentin enacarbil, with a mean dose of 567 mg/day, was examined in an open-label prospective trial of eight schizophrenia patients with akathisia. The Barnes Akathisia Rating Scale global akathisia score significantly decreased after 1 and 2 weeks of treatment when compared to baseline (P=0.01 and P=0.01, respectively). There was no worsening of psychosis (114). Other agents with limited evidence for the treatment of akathisia include benzodiazepines (clonazepam), amantadine, and clonidine.

Based on results of the various studies, it is suggested that propranolol, mirtazapine, and perhaps trazodone be considered first-line agents (89; 92). The other classes listed above could be considered if these fail or are contraindicated (for instance, propranolol should not be utilized in patients with asthma or diabetes).

An updated evidence-based guideline for the treatment of tardive dyskinesia has been provided in 2018 (07). In tardive akathisia, aside from propranolol (41), the catecholamine depletors, valbenazine and deutetrabenazine, have level A evidence (30; 42). Reserpine and tetrabenazine have also been the effective agents but at level C (13; 49). The problem with these drugs is that they have the potential to cause subacute akathisia as well. For the newer VMAT2 agents, their pharmacokinetic profile seems to make such side effects less common. Zolpidem, which is a GABA-mimetic drug and a selective agonist of the benzodiazepine receptors, and gabapentin, which enhances the activity of GABA, have also been found to be helpful in some patients with akathisia, without causing significant drowsiness (49; 121; 113). Anticholinergic agents will likely make tardive akathisia worse as they do with classical tardive dyskinesia, but there are little data on this. A case report suggests a role for electroconvulsive therapy, but further experience is needed (27). Deep brain stimulation of the subthalamic nucleus has been reported to be effective in patients with Parkinson disease who experienced severe akathisia with or without a relationship to levodopa (108). Although there are increasing data for the use of deep brain stimulation of the globus pallidus interna for classical tardive dyskinesia and tardive dystonia (115), it is not clear whether deep brain stimulation would be a suitable treatment for tardive akathisia.

References

01: Adler LA, Rotrosen J, Angrist B. Acute drug-induced akathisia. In: Factor SA, Lang AE, Weiner WJ, editors. Drug-induced Movement Disorders. 2nd ed. Malden, MA: Blackwell Futura, 2005:140-73.
02: Akagi H, Kumar TM. Lesson of the week: Akathisia: overlooked at a cost. BMJ 2002;324(7352):1506-7. PMID 12077042
03: Athanassiadis C, Karamanis A. Akathisia after long-term epidural use of droperidol. Pain 1992;50:203-4. PMID 1408317
04: Baskak B, Atbasoglu EC, Ozguven HD, Saka MC, Gogus AK. The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2007;27:289-94. PMID 17502777
05: Bayulkem K, Lopez G. Clinical approach to nonmotor sensory fluctuations in Parkinson’s disease. J Neurol Sci 2011;310:82-5. PMID 21872276
06: Berna F, Misdrahi D, Boyer L, et al. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophr Res 2015;169(1-3):255-61. PMID 26589388
07: Bhidayasiri R, Jitkritsadakula O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. J Neurol Sci 2018;389:67-75. PMID 29454493
08: Bjarke J, Gjerde HN, Jørgensen HA, Kroken RA, Løberg EM, Johnsen E. Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. Acta Neuropsychiatr 2022;34(5):282-8. PMID 35260218
09: Braude WM, Barnes TR. Late onset akathisia: an indicant of covert dyskinesia: two case reports. Am J Psychiatry 1983;140:611-12. PMID 6133460
10: Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983;143:139-50. PMID 6137254
11: Brown P. Review: drug induced akathisia in medical and surgical patients. Int J Psychiatry Med 1988;18:1-15. PMID 3294201
12: Brune M. The incidence of akathisia in bipolar affective disorder treated with neuroleptics--a preliminary report. J Affect Disord 1999;53:175-7. PMID 10360412
13: Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4:157-75. PMID 2567492
14: Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 2017;78(3): e264-78. PMID 28146614
15: Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 2018;17(3):330-40. PMID 30192088
16: Caroff SN, Cambell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatr Clin North Am 2016;39(3):391-411. PMID 27514296
17: Charton A, Greib N, Ruimy A, et al. Incidence of akathisia after postoperative nausea and vomiting prophylaxis with droperidol and ondansetron in outpatient surgery: A multicentre controlled randomized trial. Eur J Anaesthesiol 2018;35(12):966-71. PMID 29746373
18: Chinn E, Brunette ND, Driver BE, et al. Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients. Am J Emerg Med 2023;65:109-12. PMID 36603355
19: Chow CL, Kadouh NK, Bostwick JR, VandenBerg AM. Akathisia and newer second-generation antipsychotic drugs: a review of current evidence. Pharmacotherapy 2020;40(6):565-74. PMID 32342999
20: Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics 2014;11(1):166-176. PMID 24310603
21: Comella C, Goetz CG. Akathisia in Parkinson's disease. Mov Disord 1994;9:545-9. PMID 7990849
22: De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol 2012;26(5):603-17. PMID 21940761
23: Demyttenaere K, Detraux J, Racagni G, Vansteelandt K. Medication-induced akathisia with newly approved antipsychotics in patients with a severe mental illness: a systematic review and meta-Analysis. CNS Drugs 2019;33(6):549-66. PMID 31065941
24: Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985;142:499-501. PMID 3976927
25: Duncan EJ, Adler LA, Stephanides M, Sanfilipo M, Angrist B. Akathisia and exacerbation of psychopathology: a preliminary report. Clin Neuropharmacol 2000;23:169-73. PMID 10895402
26: Eichhammer P, Albus M, Borrmann-Hassenbach M, et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet 2000;96(2):187-91. PMID 10893495
27: Emmanuel T. Remission of treatment-resistant depression with tardive akathisia with electroconvulsive therapy. BMJ Case Rep 2019;12(9):e229714. PMID 31537609
28: Factor SA, Burkhard PR, Caroff S, et al. Recent developments in drug-induced movement disorders: a mixed picture. Lancet Neurol 2019;18(9):880-90. PMID 31279747
29: Factor SA. Management of tardive syndrome: medications and surgical treatments. Neurotherapeutics 2020;17(4):1694-712. PMID 32720245
30: Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology 2017;88(21):2003-10. PMID 28446646
31: Ferre S, Winkelman JW, García-Borreguero D, Belcher AM, Chang JH, Earley CJ. Restless legs syndrome, neuroleptic-induced akathisia, and opioid-withdrawal restlessness: shared neuronal mechanisms? Sleep 2024;47(3):zsad273. PMID 37864837
32: Friedman BW, Garber L, Yoon A, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology 2014;82(11):976-83. PMID 24523483
33: Friedman BW, Mulvey L, Esses D, et al. Metoclopramide for acute migraine: a dose finding randomized clinical trial. Ann Emerg Med 2011;57:475-82. PMID 21227540
34: Friedman JH. Movement disorders induced by psychiatric drugs that do not block dopamine receptors. Park Rel Disord 2020;79:60-4. PMID 32871538
35: Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28:203-9. PMID 18344731
36: Gebhardt S, Hartling F, Hanke M, et al. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry 2006;15:371-82. PMID 16648965
37: Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998;32:692-8. PMID 9640489
38: Gogtay N, Sporn A, Alfaro CL, Mulqueen A, Rapoport JL. Clozapine-induced akathisia in children with schizophrenia. J Child Adolesc Psychopharmacol. 2002;12(4):347-9. PMID 12625995
39: Haddad PM, Das A, Keyhani S, Chaudhry IB. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol 2012;26(5 Suppl):15-26. PMID 22057019
40: Haskovec L. L'akathisie. Rev Neurol 1901;9:1107-9.
41: Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA. Propranolol therapy for tardive dyskinesia: a retrospective examination. Parkinsonism Relat Disord 2016;32:124-6. PMID 27622970
42: Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 2017;174(5):476-84. PMID 28320223
43: Hauser RA, Meyer JM, Factor SA, et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr 2022;27(2):208-17. PMID 33213556
44: Hofmann M, Seifritz E, Botschev C, Krauchi K, Muller-Spahn F. Serum iron and ferritin in acute neuroleptic akathisia. Psychiatry Res 2000;93:201-7. PMID 10760378
45: Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease. JAMA 2016;316(1):40-50. PMID 27380342
46: Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66(3):366-72. PMID 16476934
47: Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 2016b;17(18):2461-70. PMID 27819145
48: Jankovic J. Leg stereotypy disorder. J Neurol Neurosurg Psychiatry 2016a;87(2):220-1. PMID 26209715
49: Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Exp Rev Neurother 2011;11:1509-23. PMID 22014129
50: Jouini L, Ouali U, Ouanes S, Djebara MB, Nacef F, Gouider R. Akathisia among patients undergoing antipsychotic therapy: prevalence, associated factors, and psychiatric impact. Clin Neuropharmacol 2022;45(4):89-94. PMID 35696611
51: Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, et al. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomized study of antipsychotic treatment. Psychopharmacology 2017;234(17):2563-70. PMID 28567698
52: Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pkialov A 3rd, Assuncao-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70:627-43. PMID 19389331
53: Kato T, Ishigooka J, Miyajima M, et al. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry Clin Neurosci 2020;74(12): 635-44. PMID 32827348
54: Kawanishi C, Onishi H, Kato D, et al. Unexpectedly high prevalence of akathisia in cancer patients. Palliat Support Care 2007;5:351-4. PMID 18044412
55: Ketter TA, Durgamb S, Landbloomc R, Macklec M, Wub X, Mathews M. Long-term safety and tolerability of asenapine: a double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder. J Affect Disord 2017;207:384-92. PMID 27755982
56: Kruse W. Persistent muscular restlessness after phenothiazine treatment. Report of 3 cases. Am J Psychiatry 1960;117:152-3. PMID 14412282
57: Kuloglu M, Atmaca M, Ustundag B, Canatan H, Gecici O, Tezcan E. Serum iron levels in schizophrenic patients with or without akathisia. Eur Neuropsychopharmacol 2003;13(2):67-71. PMID 12650948
58: Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 2009;22:293-9. PMID 19378382
59: Lang AE. Patient perception of tics and other movement disorders. Neurology 1991;41:223-8. PMID 1992365
60: Lang AE. Akathisia and the restless legs syndrome. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. 2nd ed. Baltimore: Williams & Wilkins, 1993:399-418.
61: Lang AE. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. Mov Disord 1994;9:188-92. PMID 8196681
62: Lang AE, Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987;37:477-81. PMID 3822142
63: Laoutidis ZG, Luckhaus C. 5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2014;17(5):823-32. PMID 24286228
64: Lawford BR, Barnes M, Swagell CD, et al. DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia. J Psychopharmacol 2013;27(4):343–8. PMID 23118020
65: Leong GB, Silva JA. Neuroleptic-induced akathisia and violence: a review. J Forensic Sci 2003;48(1):187-9. PMID 12570226
66: Lipinski JF, Mallya G, Zimmerman P, Pope HG. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989;50:339-42. PMID 2549018
67: Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, Soliman MA. The clinical challenges of akathisia. CNS Spectr 2015;20 Suppl 1:1-14. PMID 26683525
68: Lotia M, York MK, Strutt AM, Jankovic J. Leg stereotypy syndrome: phenomenology and prevalence. J Neurol Neurosurg Psychiatry 2018;89(7):692-5. PMID 29332008
69: Markkula J, Helenius H, Lauerma H. On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population. Nord J Psychiatry 2007;61:152-7. PMID 17454730
70: Martinez-Telleria A, Cano ME, Carlos R. Paradoxical reaction to midazolam after its use as a sedative in regional anesthesia. Rev Esp Anestesiol Reanim 1992;39:379-80. PMID 1293657
71: Mentzel TQ, Lieverse R, Bloemen O, Viechtbauer W, van Harten PN, The Genetic Risk and Outcome of Psychosis (GROUP) Investigators. High incidence and prevalence of drug-related movement disorders in young patients with psychotic disorders. J Clin Psychopharmacol 2017;37(2):231-8. PMID 28141621
72: Meyer J, Kirkland SW, Campbell S, Villa-Roel C, Rowe B. Adjuvant anticholinergic therapy for the prevention of akathisia in patients with primary headache in the emergency department: a systematic review. Acad Emerg Med 2023;30:45-52. PMID 35962748
73: Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22(1):73-81. PMID 10647977
74: Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional neuroleptics. J Clin Psychiatry 1998;59:69-75. PMID 9501888
75: Miodownik C, Lerner V, Statsenko N, Miodownik C. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clin Neuropharmacol 2006;29:68-72. PMID 16614537
76: Mohr P, Volavka J. Ladislav Haskovec and akathisia: 100th anniversary. Br J Psychiatry 2002;181:537. PMID 12456534
77: Mokhtari A, Yip O, Alain J, Berthelot S. Prophylactic administration of diphenhydramine to reduce neuroleptic side effects in the acute care setting: a systematic review and meta-analysis. J Emerg Med 2021;60(2):165-74. PMID 33131965
78: Mossaheb N, Kaufmann RM. Role of aripiprazole in treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 2012;8:235-44. PMID 22701324
79: Musco S, McAllister V, Caudle I. Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment. Ther Adv Psychopharmacol 2020;10:2045125320937575. PMID 32922732
80: Nilles C, Amorelli G, Pringsheim TM, Martino D. “Unvoluntary” movement disorders: distinguishing between tics, akathisia, restless legs, and stereotypies. Semin Neurol 2023;43(1):123–46. PMID 36854393
81: O'Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord 2015;30(12):1681-7. PMID 26346941
82: Olsen JC, Keng JA, Clark JA. Frequency of adverse reactions to prochlorperazine in the ED. Am J Emerg Med 2000;18:609-11. PMID 10999579
83: Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002a;25(6):300-2. PMID 12469001
84: Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol 2002b;59:421-4. PMID 11890847
85: Pannu V, Udongwo N, Imburgio S, et al. Adverse events of SARS-CoV-2 therapy: A pharmacovigilance study of the FAERS database. Ann Pharmacother 2024;58(2):105-9. PMID 37144730
86: Parksepp M, Ljubajevb U, Tahtc K, Jannod S. Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients. Nord J Psychiartry 2016;70(7):498-502. PMID 27093226
87: Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2014;13(1):100-12. PMID 24331796
88: Pena MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2011;26:147-52. PMID 20818603
89: Poyurovsky M. Acute antipsychotic induced akathisia revisited. Brit J Psychiatry 2010;196:89-91. PMID 20118449
90: Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 2006;59:1071-7. PMID 16497273
91: Poyurovsky M, Weizman A. Treatment of antipsychotic-induced akathisia: role of Serotonin 5‑HT2a receptor antagonists. Drugs 2020;80(9):871-82. PMID 32385739
92: Pringsheim T, Gardner D, Addington D, et al. The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry 2018;63(11):719-29. PMID 29685069
93: Prueter C, Habermeyer B, Norra C, Kosinski CM. Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease. Mov Disord 2003;18(6):712-3. PMID 12784279
94: Ranjan S, Chandra PS, Chaturvedi SK, Prabhu SC, Gupta A. Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine. Ann Pharmacother 2006;40:771-4. PMID 16569791
95: Rashid A, Baile W, Olubajo T, De La Garza R 2nd. Incidence of antiemetic-induced akathisia in patients at a comprehensive cancer center. Psychooncology 2018;27(4):1338-40. PMID 29193507
96: Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2006;(4):CD003727. PMID 17054182
97: Reutfors J, Clapham E, Bahmanyar S, et al. Suicide risk and antipsychotic side effects in schizophrenia: nested case-control study. Hum Psychopharmacol 2016;31(4):341-5. PMID 27108775
98: Rissardo JP, Caprara ALF. Mirtazapine-associated movement disorders: a literature review. Tzu Chi Medical J 2020; 32(4): 318-30. PMID 33163376
99: Sachdev P, Loneragan C. Acute drug-induced akathisia is not associated with low serum iron status. Psychopharmacology 1991;103:138-9. PMID 1672456
100: Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD. Olanzapine versus haloperidol treatment in first episode psychosis. Am J Psychiatry 1999;156:79-87. PMID 9892301
101: Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci 2018;389:35-42. PMID 29506749
102: Schoretsanitis G, Nikolakopoulou A, Guinart D, Correll CU, Kane JM. Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: a systematic review and meta-analysis of cross-sectional studies. Eur Neuropsychopharmacol 2020;35:1-11. PMID 32444336
103: Scorr LM, Factor SA. VMAT2 inhibitors for the treatment of tardive dyskinesia. J Neurol Sci 2018;389:43-7. PMID 29433808
104: Seemuller F, Lewitzka U, Bauer M, et al. The relationship of akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry 2012a;45(7):292–6. PMID 22614116
105: Seemuller F, Schennach R, Mayr A, et al. Akathisia and suicidal ideation in first-episode schizophrenia. J Clin Psychopharmacol 2012b;32(5):694-8. PMID 22926606
106: Shah R, Grover S, Maheshwari U, Kate N, Malhotra N. Acute akathisia with quetiapine: a case report and review of the literature. Ind J Pharmacol 2010;42:416-17. PMID 21189919
107: Shams-Alizadeh N, Maroufi A, Asadi Z, Rahmani K, Hassanzadeh K. Trazodone as an alternative treatment for neuroleptic-associated akathisia: a placebo-controlled, double-blind, clinical trial. J Clin Psychopharmacol 2020;40(6): 611-14. PMID 33044356
108: Shin HW, Chang JW, Kang SY, Sohn YH. Effects of chronic subthalamic stimulation on intractable akathisia in Parkinson's disease. Mov Disord 2010;25(5):650-2. PMID 20213829
109: Skidmore F, Weiner WJ, Burke R. Neuroleptic-induced tardive dyskinesia variants. In: Factor SA, Lang AE, Weiner WJ, editors. Drug-induced Movement Disorders. 2nd ed. Malden, MA: Blackwell Futura, 2005: 257-84.
110: Stahl SM, Lonnen AJ. The mechanism of drug-induced akathisia. CNS Spectr 2011. [Epub ahead of print] PMID 21406165
111: Steffens DC, Nelson JC, Eudicone JM, et al. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. Int J Geriatr Psychiatry 2011;26(6):564-72. PMID 20827794
112: Stryjer R, Rosenzcwaig S, Bar F, Ulman AM, Weizman A, Spivak B. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind crossover study. Clin Neuropharmacol 2010;33(5):219-22. PMID 20838215
113: Sullivan MA, Wilbur R. Gabapentin pharmacotherapy for antipsychotic-induced akathisia: single-patient experiment and case report. Ther Adv Psychopharmacol 2014;4(2):100-2. PMID 24688760
114: Takeshima M, Ishikawa H, Kanbayashi T, Shimizu T. Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study. Neuropsychiatr Dis Treat 2018;14:3179-84. PMID 30538475
115: Testini P, Factor SA. Treatment of tardive dystonia: a review. Dystonia 2023. [Epub ahead of print]
116: Tripathi R, Reich SG, Scorr L, Guardiani E, Factor SA. Lurasidone-induced tardive syndrome. Mov Disord Clin Pract 2019;6(7):601-4. PMID 31538095
117: Trottier ED, Bailey B, Lucas N, Lortie A. Prochlorperazine in children with migraine: a look at its effectiveness and rate of akathisia. Am J Emerg Med 2012;30(3):456-63. PMID 21296523
118: Tura P, Erdur B, Aydin B, Turkcuer I, Parlak I. Slow infusion metoclopramide does not affect the improvement rate of nausea while reducing akathisia and sedation incidence. Emerg Med J 2012;29(2):108-12. PMID 21292793
119: Vieta E, Sachs G, Chang D, et al. Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania. J Psychopharmacol 2021;35(8):971-82. PMID 33691517
120: Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) 2013a;3. PMID 23858394
121: Waln O, Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord 2013b;28(12):1748-9. PMID 23637028
122: Ward NG. Akathisia associated with droperidol during epidural anesthesia. Anesthesiology 1989;71:786-7. PMID 2817476
123: Wijemanne S, Jankovic J, Evans RW. Movement disorders from the use of metoclopramide and other antiemetics in the treatment of migraine. Headache 2016;56(1):153-61. PMID 26573884
124: Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59(3):408-13. PMID 12177375
125: Wu H, Siafis S, Wang D, et al. Antipsychotic-induced akathisia in adults with acute schizophrenia: a systematic review and dose-response meta-analysis. Eur Neuropsychopharmacol 2023;72:40-9. PMID 37075639
126: Yatham LN, Vieta E, Earley W. Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial. Int Clin Psychoparmacol 2020;35(3):147-56. PMID 32058426
127: Yazici KU, Percinel I. Atomoxetine-associated akathisia a case report. J Clin Psychopharmacol 2014;34(6):770-2. PMID 25203465
128: Yoshida K, Takeuchi H. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Behav Brain Res 2021;402:113098. PMID 33417992
129: Yoshimura B, Sato K, Sakamoto S, Tsukahara M, Yoshimura Y, So R. Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. Psychopharmacology (Berl) 2019;236(2):723-30. PMID 30443794
130: Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y) 2014;4:266. PMID 25374768

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Stewart A Factor DO

Dr. Factor of the Emory University School of Medicine received research grants from Biohaven, Neurocrine, Prilenia, SPARC, US World Meds, and Voyager as a site investigator; consulting fees from Biogen, Lundbeck, and Signant; and an educational grant from Boston Scientific.
See Profile

Editor

Robert Fekete MD

Dr. Fekete of New York Medical College received consultation fees from Acadia Pharmaceutical, Acorda, Adamas/Supernus Pharmaceuticals, Amneal/Impax, Kyowa Kirin, Lundbeck Inc., Neurocrine Inc., and Teva Pharmaceutical, Inc.
See Profile

Former Authors

David E Riley MD
Joseph Jankovic MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Akathisia

Associated Disorders

Parkinson disease
Postencephalitic parkinsonism
Psychiatric disorders

Differential Diagnosis

schizophrenic stereotypies
tardive dyskinesia
drug withdrawal
restless legs syndrome
tics
- SSRI-induced movement disorders
- lithium-induced movement disorders

Also Relevant

Acute drug-induced movement disorders
Catatonia
Periodic limb movements
Restless legs syndrome
Sleep and parkinsonism
- Status migrainosus
- Stereotypies
- Tardive dyskinesia
- Tardive dystonia

Clinical Categories

Movement Disorders

Akathisia …

Akathisia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

Akathisia

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Hemifacial spasm

Wilson disease

Neuroacanthocytosis

Restless legs syndrome

Dementia in Parkinson disease

ALS-like disorders of the Western Pacific

Sleep-related leg cramps

Sleep and cerebral degenerative disorders

This is an article preview.
Start a Free Account
to access the full version.